Baidu
map

Brit J Cancer:雄激素受体信号削弱了多烯紫杉醇的疗效

2020-10-15 AlexYang MedSci原创

前列腺癌中,雄激素受体(AR)信号能够驱动肿瘤生长和治疗抗性。最近的临床数据显示,多烯紫杉醇联合雄激素阻断治疗能够改善激素敏感性疾病治疗结果。

前列腺癌中,雄激素受体(AR)信号能够驱动肿瘤生长和治疗抗性。最近的临床数据显示,多烯紫杉醇联合雄激素阻断治疗能够改善激素敏感性疾病治疗结果。

最近,有研究人员研究了是否睾酮和AR信号在去势抵抗性前列腺癌中能够干扰多烯紫杉醇(CRPC)的治疗效果。研究发现,睾酮的补充明显的削弱了多烯紫杉醇在CRPC模型肿瘤中的积累,并导致小管蛋白稳定和抗肿瘤活性降低。更多的是,睾酮与多烯紫杉醇能够相互竞争药物转运体OATP1B3。无论多烯紫杉醇诱导的小管素稳定如何,睾酮的AR信号均能抵消多烯紫杉醇的疗效。AR通路激活也可以逆转多烯紫杉醇在体内治疗的长期肿瘤退化。

睾酮补充强烈削弱多烯紫杉醇的疗效和积累

最后,研究人员指出,为了优化多烯紫杉醇的疗效,需要抑制雄激素水平和AR信号。该研究为CRPC中联合靶向治疗药物和多烯紫杉醇治疗时需要继续最大限度地抑制AR信号提供了证据。

原始出处:

Lisanne Mout, Jan M. Moll, Mingqing Chen et al. Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer. Brit J Cancer. Sep 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=894333, encodeId=826189433352, content=新观点!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:19:30 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350578, encodeId=f61213505e8b4, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Oct 17 03:26:31 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417365, encodeId=a682141e36561, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Sat Oct 17 03:26:31 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032685, encodeId=e41c1032685aa, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Oct 15 15:26:31 CST 2020, time=2020-10-15, status=1, ipAttribution=)]
    2020-10-25 ms3000000449926787

    新观点!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=894333, encodeId=826189433352, content=新观点!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:19:30 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350578, encodeId=f61213505e8b4, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Oct 17 03:26:31 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417365, encodeId=a682141e36561, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Sat Oct 17 03:26:31 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032685, encodeId=e41c1032685aa, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Oct 15 15:26:31 CST 2020, time=2020-10-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=894333, encodeId=826189433352, content=新观点!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:19:30 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350578, encodeId=f61213505e8b4, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Oct 17 03:26:31 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417365, encodeId=a682141e36561, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Sat Oct 17 03:26:31 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032685, encodeId=e41c1032685aa, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Oct 15 15:26:31 CST 2020, time=2020-10-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=894333, encodeId=826189433352, content=新观点!, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Sun Oct 25 15:19:30 CST 2020, time=2020-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350578, encodeId=f61213505e8b4, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Oct 17 03:26:31 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417365, encodeId=a682141e36561, content=<a href='/topic/show?id=28ca43332b5' target=_blank style='color:#2F92EE;'>#多烯紫杉醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43332, encryptionId=28ca43332b5, topicName=多烯紫杉醇)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63eb3265522, createdName=zhangmingxiang, createdTime=Sat Oct 17 03:26:31 CST 2020, time=2020-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032685, encodeId=e41c1032685aa, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Oct 15 15:26:31 CST 2020, time=2020-10-15, status=1, ipAttribution=)]
    2020-10-15 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

Prostate Cancer P D:前列腺癌患者的抑郁、焦虑和自杀:观察性研究的系统回顾和元分析

前列腺癌的精神影响越来越受重视,且对肿瘤和功能结果有重要影响。然而,对并发抑郁症、焦虑和自杀的研究结果仍存在差异。最近,有研究人员进行了观察性回顾研究,从而建立前列腺癌患者这些结果的普适性和比例的最佳

Brit J Cancer:前列腺癌发生率和死亡率相关的新生化因素调查

虽然前列腺癌是癌症死亡的主要原因,但其病因学并不十分清楚。最近,有研究人员在英国生物库中鉴定了与前列腺癌发病率和死亡率有关的新型生化因素。

Cell Death & Disease:miR-361-3p能够增加前列腺癌对恩杂鲁胺的敏感性

缺少配体结合域的雄激素受体剪接变异体7(ARv7)越来越被认为是导致前列腺癌(PCa)患者对恩杂鲁胺(Enz)耐药的关键因子。然而,ARv7的表达是如何被调控的详细机制以及它是否需要其他因子来诱导最大

Oncogene:前列腺癌中雄激素受体剪接变异体-7(AR-V7)对第二代雄激素受体信号抑制剂耐药中的作用

截短了的雄激素受体剪接变异体-7(AR-V7)在前列腺癌生物学中的作用是一个未解决的问题。它是简单的第二代雄激素受体信号抑制剂(ARSi)如醋酸阿比特龙(Abi)和恩杂鲁胺(Enza)耐药的标志,还是

为什么得前列腺癌的人越来越多?医生的答案有4个

前列腺癌是一种常见的男性恶性肿瘤,且近几年来发病人数有逐渐上升的趋势。这种癌症早期发现治愈率较高,因此高危人群要定时进行筛查,特别是肥胖的人群。另外,一定要关注自身是否出现排尿问题,如果出现症状要及时

Oncogene:EGFR上调的LIFR能够促进前列腺癌SUCLG2依赖的去势抗性和神经内分泌分化

神经内分泌(NE)分化是雄激素剥夺治疗(ADT)后前列腺癌的一种普遍的表型变化,并最终发展为侵袭性亚型。然而,导致前列腺癌代谢紊乱和NE分化的信号通路仍不清楚。

Baidu
map
Baidu
map
Baidu
map